1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Vitrolife AB

Vitrolife AB

0YAY.IL
Vitrolife ABGB flagInternational Order Book
89.45
SEK
+0.05
- -
12.11BMarket Cap
Vitrolife AB
0YAY.IL
(International Order Book)

Recent

price

89.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.04
3.15
3.7
4.57
5.11
6.65
7.89
9.64
10.61
13.64
11.47
14.67
23.89
25.94
26.65
25.4
26.13
Revenue per Share
0.3
0.31
3.41
0.57
1.09
1.68
1.75
2.43
2.85
3.53
2.64
2.97
2.91
-28.44
3.79
-37.01
3.36
Basic EPS, GAAP
0.07
0.16
0.43
0.98
1.37
1.57
1.54
2.78
1.56
3.01
3.1
2.8
4.05
4.71
5.21
2.87
4.39
Free Cash Flow per Basic Share
0.1
0.12
0.14
0.12
0.2
0.3
0.48
0.53
0.75
0.85
- -
0.77
0.81
0.85
1
1.1
1.1
Dividend per Share
3.33
3.51
2.8
3.17
6.46
7.77
9.38
11.29
13.75
16.53
18.54
113.12
123.56
93.93
100.7
58.28
98.05
Book Value per Share
1.43
1.42
0.62
1.09
1.29
3.02
3.4
5.69
7.05
9.36
12.07
-16.43
-13.19
-8.72
-6.08
-2.84
-5.39
Tangible Book Value per Share
98
98
98
99
100
109
109
109
109
109
109
115
135
135
135
135
135
Basic Weighted Avg Shares
298
308
362
453
511
722
856
1,046
1,151
1,480
1,246
1,681
3,234
3,512
3,609
3,440
3,539
Sales/Revenue/Turnover
11.18
7.06
13.84
17.41
26.61
28.87
28.97
32.82
33.79
32.98
30.17
25.46
20.01
21.01
21.95
16.69
19.36
Operating Margin (%)
- -
17
19
35
23
53
54
67
85
99
84
109
396
425
442
427
121
Depreciation Expense
29
30
334
56
109
183
190
264
310
383
287
341
394
-3,851
513
-5,012
455
Net Income, GAAP
29.26
32.06
46.63
28.94
25.49
19.17
23.19
22.38
22.05
22.09
21.39
25.22
26.63
- -
23.74
- -
- -
Effective Tax Rate (%)
9.72
9.86
92.2
12.43
21.37
25.31
22.24
25.2
26.9
25.86
23.03
20.29
12.18
-109.65
14.21
-145.7
12.86
Profit Margin (%)
70
86
63
88
149
283
317
575
698
948
1,237
453
951
1,357
1,652
1,477
1,542
Working Capital
41
56
58
22
60
36
- -
- -
- -
61
49
2,026
2,043
1,942
1,929
1,562
1,840
LT Debt
326
344
279
316
703
845
1,020
1,229
1,496
1,798
2,017
15,341
16,740
12,723
13,641
7,895
13,282
Total Equity
6.72
3.7
6.82
15.34
17.12
19.35
18.98
22.93
21.95
22.25
14.83
3.21
2.58
- -
3.95
- -
4.48
Return on Invested Capital (%)
10.12
9.22
87.56
16.14
19.16
21.81
19.49
23
22.68
22.76
14.54
3.47
2.32
- -
3.82
- -
2.99
Return on Capital (%)
9.08
9.08
107.54
19.02
21.5
23.68
20.46
23.5
22.78
23.29
15.07
3.93
2.46
-26.15
3.89
-46.55
3.45
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
160
151
153
LT Borrowings
1,837
1,710
1,758
LT Finance Leases
92
90
82
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
135
135
135
Market Capitalization
29,053
21,597
18,834

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,357
2,279
2,183
Cash, Cash Equivalents & STI
1,135
1,054
921
Accounts Receivable, Net
648
634
635
Inventories
422
413
430
Total Current Liabilities
705
605
641
Payables & Accruals
- -
- -
- -
ST Debt
160
151
153
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.61%
122.16%
-42.12%
Free Cash Flow
17.82%
9.64%
-44.96%
Net Income, GAAP
-217.47%
-446.66%
-1,077%
Sales/Revenue/Turnover
19.75%
26.81%
-4.68%
Total Cash Common Dividend
- -
10.54%
10.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
841
941
867
959
3,609
2025
842
871
891
- -
3,440
2026
807
857
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.85
1.06
0.86
1.03
3.79
2025
0.74
0.74
-39.24
- -
-37.01
2026
0.75
0.95
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
- -
- -
1
2025
- -
1.1
- -
- -
1.1
2026
- -
1.1
- -
- -
- -
Similar Companies
Wellness Center USA, Inc. (WCUI)
Access Bio, Inc. (950130.KQ)
GKB Ophthalmics Limited (GKB.BO)
Osang Healthcare Co.,Ltd (036220.KQ)
Dentas Co., Ltd. (6174.T)
Prolight Diagnostics (PRLD.ST)
Business
Vitrolife AB is a Sweden-based developer, manufacturer, and provider of advanced life science and reproductive health solutions, specializing in cellular therapies and assisted reproduction technologies. The company focuses on product categories including ART media and equipment; cell culturing and embryo transfer systems; embryo biopsy and vitrification media; sperm preparation and semen analysis tools; diagnostic assays and related consumables; and laboratory automation solutions. Vitrolife operates through multiple brands and product lines designed to support fertility clinics, embryology laboratories, and research institutions. Latest major company changes include recent strategic partnerships and collaborations within the fertility and biotechnology sectors; expansion of product offerings through new ART media formulations and associated consumables; ongoing acquisitions and integrations to broaden portfolio and geographic reach; and organizational refinements to support accelerated product development and market penetration across key regions. Industry context and segments: fertility solutions, assisted reproduction technology, cellular therapy support, laboratory consumables and equipment; target markets include fertility clinics, hospitals, research institutions, and biopharma partners. Geographic footprint spans Europe, North America, Asia-Pacific, and other regions, with headquarters in Gothenburg, Sweden, and founding year dating to the late 20th century. Subsidiaries and parent-company relationships align Vitrolife with a network of affiliated entities delivering global support, distribution, and regulatory compliance.